Home › Ovarian Cancer › North Carolina › Durham
Ovarian Cancer clinical trials in Durham, NC
27 studies for Ovarian Cancer are looking for participants at sites in and around Durham (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
The Vanguard Study: Testing a New Way to Screen for Cancer
RecruitingHealthy volunteers welcome
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi away
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
RecruitingPhase 2/3
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi away
- University of North Carolina-Hillsborough Campus, Hillsborough · 13 mi away
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecruitingPhase 2
- Duke University Medical Center, Durham
A Study of PHST001 in Advanced Solid Tumors
RecruitingPhase 1
- Duke Cancer Institute, Durham
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- Duke University, Durham
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RecruitingPhase 2
- University of North Carolina Medical Center /ID# 275307, Chapel Hill · 10 mi away
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RecruitingPhase 2
- Site 0259 - Duke Cancer Center, Durham
DESTINY-PANTUMOUR04
RecruitingObservational study
- Research Site, Durham
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
RecruitingPhase 3
- Duke Cancer Institute, Durham
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RecruitingPhase 1
- Duke University Medical Center, Durham
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
RecruitingPhase 3
- Duke Cancer Center ( Site 0012), Durham
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RecruitingObservational study
- UNC- Chapel Hill, Chapel Hill · 10 mi away
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
RecruitingPhase 3
- Duke, Durham
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Recruiting
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi away
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
RecruitingPhase 3
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi away
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
RecruitingPhase 1/2
- Duke University, Durham
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RecruitingPhase 3
- UNC Hospital, Chapel Hill · 10 mi away
Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
RecruitingPhase 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi away
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
RecruitingPhase 3
- Duke Cancer Center, Durham
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
Recruiting
- Duke Cancer Center, Durham
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
RecruitingPhase 1
- Site 0259, Durham
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
Recruiting
- Duke University Hospital, Durham
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
RecruitingPhase 1/2
- Duke Cancer Center/ DUMC, Durham
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RecruitingPhase 1
- Duke Cancer Institute, Durham
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
RecruitingPhase 2
- Duke Cancer Center, Durham
Multimedia Aid for Genetic Testing in Gynecologic Oncology
Recruiting
- Univeristy of North Carolina at Chapel Hill, Chapel Hill · 10 mi away
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mi away
About Ovarian Cancer
Ovarian cancer is a cancerous tumor that forms in the tissues of an ovary. The ovaries are a pair of female reproductive glands that make eggs and female hormones.
More about Ovarian Cancer on MedlinePlus
Ovarian Cancer trials in other cities
- Houston, TX89 studies
- New York City, NY69 studies
- Boston, MA61 studies
- Los Angeles, CA50 studies
- Nashville, TN49 studies
- Arlington, VA46 studies
- Philadelphia, PA44 studies
- Columbus, OH39 studies
- St. Louis, MO38 studies
- Chicago, IL36 studies
- San Antonio, TX31 studies
- Cleveland, OH30 studies
Other studies in Durham
- Breast Cancer64 studies
- Cancer (all types)58 studies
- Non-Small Cell Lung Cancer39 studies
- Multiple Myeloma37 studies
- Acute Myeloid Leukemia33 studies
- Metastatic Cancer33 studies
- Prostate Cancer32 studies
- Lung Cancer32 studies
- Colorectal Cancer28 studies
- Chronic Lymphocytic Leukemia27 studies
- Heart Failure26 studies
- Pancreatic Cancer24 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.